Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages mdv395
Publisher
Oxford University Press (OUP)
Online
2015-09-20
DOI
10.1093/annonc/mdv395
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.
- (2017) G. Bianchini et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
- (2014) Xuanming Yang et al. CANCER CELL
- Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)
- (2014) S Loi et al. CANCER RESEARCH
- Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
- (2014) A. Prat et al. CLINICAL CANCER RESEARCH
- The immune system and response to HER2-targeted treatment in breast cancer
- (2014) Giampaolo Bianchini et al. LANCET ONCOLOGY
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
- (2014) E. Cha et al. Science Translational Medicine
- The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer
- (2013) C. Y. Slaney et al. CANCER RESEARCH
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Tumor-Associated Immune Parameters for Personalized Patient Care
- (2013) F. Pages Science Translational Medicine
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Abstract 4417: Induction of colonic cre-recombinase expression in carbonic anhydrase1-cre transgenic mice by dextran sulfate sodium
- (2012) Robert L. Johnson et al. CANCER RESEARCH
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis
- (2012) Michail Ignatiadis et al. JOURNAL OF CLINICAL ONCOLOGY
- Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
- (2012) Bradley N Bidwell et al. NATURE MEDICINE
- The Two Faces of Interferon- in Cancer
- (2011) M. R. Zaidi et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer
- (2010) G. Bianchini et al. CANCER RESEARCH
- B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression
- (2010) Andrea Borgerding et al. EXPERIMENTAL HEMATOLOGY
- Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers
- (2010) Giampaolo Bianchini et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started